Sun Pharma has agreed a takeover deal with US biotech Checkpoint Therapeutics, which recently claimed FDA approval for its first drug but is also running low on cash. The Indian pharma group ...

A phase 3 trial of intralesional cemiplimab in patients with early-stage cutaneous SCC, newly underway at GW and multiple other sites, will look at how well the immune checkpoint inhibitor ... from ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Incyte’s Hervé Hoppenot is hanging up his hat after spending more than a decade building the company into the ...

Sun Pharmaceutical Industries, operating in the Pharmaceuticals sector and classified as a Largecap on the BSE, currently has its share price at ₹1688. The stock has experienced fluctuations ...

India's Sun Pharmaceutical has signed an agreement to acquire US biotech Concert Pharmaceuticals and its lead drug deuroxilitinib, in phase 3 testing for alopecia areata, a leading cause of hair loss.

Piers Ingram, founder and CEO of Singapore-based Hummingbird Bioscience and its U.S. spin-off Callio Therapeutics, is quietly ...